Case Report

Anasarca, Fever, Thrombocytopenia, Organomegaly, and Multiorgan Failure in a 24-Year-Old Pregnant Woman

Guillaume Morel,1 Joy Mootien,2 Philippe Guiot,2 and Khaldoun Kuteifan2

1Service d’Hématologie, CHU de Strasbourg, 67000 Strasbourg, France
2Service de Réanimation Médicale, GHRMSA, 68100 Mulhouse, France

Correspondence should be addressed to Khaldoun Kuteifan; kuteifank@ghrmsa.fr

Received 28 March 2017; Accepted 30 May 2017; Published 22 June 2017

1. Background

Castleman disease is a nontumoral lymphoproliferative disorder initially described by Castleman and Towne in 1954 [1] usually characterized as either unicentric (UCD) or multicentric Castleman disease (MCD). UCD is an isolated lymphadenopathy without symptoms except those due to the tumoral mass while MCD is defined by the presence of diffuse lymph adenopathy and hepatosplenomegaly associated with systemic inflammatory manifestations: fever, asthenia, and weight loss. Laboratory abnormalities commonly include elevated inflammatory markers, microcytic anemia, hypergammaglobulinemia, and hypoalbuminemia [2]. Coombs test can also be positive. MCD is highly associated with HIV infection and these patients are also coinfected by HHV8 [3]. There is also a cohort of MCD patients without HIV and HHV8 coinfection defined as idiopathic multicentric Castleman disease (iMCD) [4]. TAFRO syndrome is a distinct subtype of iMCD characterized by the association of thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly [5]. The first description of TAFRO syndrome was published in 2010 by Takai et al. [6] who reported the case of three patients presenting these symptoms with histological findings compatible with iMCD. Some case reports or case series followed this first description. We report hereby the first case of TAFRO syndrome occurring in a Caucasian pregnant woman.

2. Case Report

A Caucasian 24-year-old woman, gravida 1, para 1 at 34 weeks of gestation, presented to our obstetric emergency department. The patient had no medical history and the pregnancy period was going well. One week before admission to our hospital, she noticed progressive weight gain associated with bilateral lower leg oedema. She also reported dyspnea, chest tightness, anorexia, and asthenia. The blood pressure was normal. Clinical exam also revealed hyperreflexia, hepatosplenomegaly, and diffuse supracentimetric lymph adenopathy. Laboratory tests were remarkable for moderate thrombocytopenia (138×10^9/L) and hyponatremia (125 mmol/L) as well as an increase of C-reactive protein (194 mg/L) and uric acid (607 μmol/L). Renal impairment
Figure 1: Computerized tomography scan showing bilateral pleural effusion and ascites. Presence of a right axillary adenopathy and hepatosplenomegalry.

was not observed though the patient was oliguric. Dipstick urine test did not reveal proteinuria.

Finally, three days after her admission a cesarean section was performed due to the bad tolerance. She gave birth to a girl weighing 2,650 grams with Apgar scores of 3 and 9. The surgery was smooth but the presence of ascites was noticed. The next days, chest pain and hyperreflexia disappeared but edema got worse with a total weight gain of 10 kg. Respiratory distress came out and the patient was oliguric despite diuretics as well as fever and thrombocytopenia got deeper to $50 \times 10^9/L$ associated with epistaxis. Computerized tomography scan showed diffuse superficial and deep lymphadenopathy, pleural effusions, ascites, and massive hepatosplenomegalry (Figure 1).

Two days later the patient was transferred to our intensive care unit, requiring mechanical ventilation for acute respiratory distress and continuous renal replacement for acute renal failure. She also became hypotensive and needed pressor support. Hemodynamic monitoring revealed hyperdynamic and vasoplegic profile. Myocardial function was preserved at transthoracic echocardiography. Table 1 shows the evolution of biological parameters during ICU hospitalization.

First-line large spectrum antibiotics (Piperacillin-Tazobactam and Ciprofloxacin) were started but fever and inflammatory syndrome kept going. A second line antibiotic was then introduced (Meropenem, Vancomycin, and Amikacin) together with Caspofungin two days later. All blood, protected samples of lower respiratory tract secretions and urinary cultures were sterile. Serological tests for HIV, Hepatitis B and C virus, CMV (for both IgM and IgG), EBV (for both IgM and IgG), HTLV1, and Parvovirus were negative. PCR blood test did not reveal viral replication for CMV and HHV8. Exhaustive immune tests were also not contributive, and the serum complement was normal. Neither monoclonal nor polyclonal elevation of gamma globulin was found. Only serum level of IL-6 was increased (842 pg/mL). Bone marrow biopsy revealed a hypercellular marrow with megakaryocytic hyperplasia associated with the presence of reticulin fibrosis. Tumoral burden was assessed by positron emission tomography using $[18F]$ fluorodeoxyglucose and showed diffuse supra- and infradiaphragmatic adenopathy. All tumoral lymph nodes were smaller than two centimeters and the metabolic activity was low (Figure 2).

The diagnosis of TAFRO-like syndrome was proposed. Nine days after ICU admission, steroid boluses of 1g of methylprednisolone per day during three days were started followed by 1.5 mg/kg/day.

Spectacular clinical and biological improvement followed steroid introduction. Fever disappeared and blood pressure became normal allowing the weaning of pressor support. We also noticed a decline of pleural effusions and ascites which conduced to respiratory improvement and we preceded extubation eleven days later. Dialysis was stopped at day 30 as the renal function improved. Tumoral infiltration also declined. ICU acquired neuromyopathy was observed but got better with intensive kinesitherapy. Finally thirty-eight days after ICU admission the patient was transferred to internal medicine unit and rehabilitation started.

3. Discussion

Diagnostic criteria of TAFRO syndrome [7] include presence of histological criteria (compatible with pathological findings of lymph node as TAFRO-iMCD and negative LANA-1 for HHV8), three of five major criteria (thrombocytopenia, anasarca, fever, reticulbin fibrosis, and organomegalry), and one of two minor criteria (hyper/normoplasia of megakaryocytes in bone marrow or high levels of serum ALP without markedly elevated serum transaminase) which are needed to meet the diagnosis of TAFRO syndrome. Our patient met all the major and minor criteria but unfortunately we could not have a histological analysis of a lymph adenopathy. However we had considered this diagnostic and started treatment by steroids. Moreover we quickly observed a significant improvement of hemodynamic, respiratory, and hematological and renal parameters which strengthened our diagnosis.

As systemic inflammatory manifestations are important, TAFRO syndrome can be mistaken with severe autoimmune diseases [8], systemic infections, hematological malignancies, or hemophagocytic lymphohistiocytosis. These syndromes were proposed but none of them were absolutely compatible with the diagnostic. There was no evidence for underlying autoimmune disease which could explain systemic inflammation or renal failure. C-reactive protein was high but all microbiological cultures serology and PCR were negative and ruled out a possible systemic infection. On the other hand, a tumoral syndrome was present but bone marrow biopsy did...
Table 1: Evolution of biological tests in ICU.

| Day 0          | Day 4          | Day 7          | Day 9          | Day 12         | Day 16         | Day 20         | Day 30         |
|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Admission in ICU | Pressor support | Dialysis       | Steroids       | Stop pressor support | Stop ventilation | Stop dialysis   |
| Leucocyte count (G/L) | 17.3           | 27.9           | 24.1           | 36.4           | 38.1           | 23.5           | 27.9           | 19.8           |
| Hemoglobin (g/dL)   | 9.2            | 6.9            | 8.6            | 8.1            | 7.6            | 7.9            | 8.2            | 7.8            |
| Platelets (G/L)     | 54             | 30             | 26             | 22             | 30             | 59             | 183            | 116            |
| Serum creatinine (μmol/L) | 75             | 137            | 151            | 153            | 99             | 86             | 73             | 60             |
| Fibrinogen (mg/dL)  | 930            | 780            | 790            | 530            | 520            | 640            | 610            | 410            |
| C-reactive protein (mg/dL) | 34.3          | 28.9           | 31.4           | 29.5           | 21.4           | 2.9            |                |                |
| Serum ferritin (ng/mL) | 526           | 939            | 1053           |                |                |                |                | 261            |
| Triglycerides (mg/dL) | 240            |                |                |                |                |                | 430            |                |
| Albumin (g/dL)      | 1.6            | 1.8            | 2              | 2.4            | 2.5            |                |                | 2.9            |
| Aspartate amino-transferase (IU/L) | 7              | 6              | 9              | 43             | 134            | 46             | 35             |                |
| Alanine amino-transferase (IU/L) | 21             | 32             | 52             | 131            | 155            | 81             | 18             |                |
| Alkaline phosphatase (IU/L) | 479           | 355            | 176            | 204            | 655            | 949            | 261            |                |
| Lactate dehydrogenase (IU/L) | 240           | 443            | 497            | 505            |                |                |                | 161            |
| Blood lactate (mmol/L) | 1.25          | 0.6            | 2.7            | 2.7            | 2.2            | 2.1            | 1.4            | 3              |

Reference Ranges. Leucocyte count (4.0–10 G/L), hemoglobin (11–16 g/dL), platelets (150–450 G/L), serum creatinine (45–90 μmol/L), fibrinogen (200–400 mg/dL), C-reactive protein (0–0.4 mg/dL), serum ferritin (12–180 ng/mL), triglycerides (43–148 mg/dL), albumin (3.2–5.5 g/dL), aspartate amino-transferase (0–40 IU/L), alanine amino-transferase (0–40 IU/L), alkaline phosphatase (115–359 IU/L), lactate dehydrogenase (85–250 IU/L), and blood lactate (0.6–2.1 mmol/L).

Figure 2: Positron emission tomography using [18F] fluorodeoxyglucose showing diffuse infracentimetric supra and infradiaphragmatic adenopathy with low metabolic activity.
not find tumoral infiltration and PET scanner revealed small lymph nodes with low metabolic activity and consequently not compatible with an aggressive lymphoproliferative disorder. Furthermore H-score [9] was not increased, particularly due to the low ferritin level, and excluded the probability of hemophagocytic lymphohistiocytosis. Finally only TAFRO-like syndrome was the compatible diagnostic.

First-line steroid is the usual treatment for TAFRO syndrome [10] and can bring about sustained remissions. In case of relapse or refractory disease, several immunosuppressive drugs have been proposed and also associated with successful disease control. For example Cyclosporine A [11] may be an alternative therapy for refractory TAFRO syndrome. Anti-IL-6 receptor monoclonal antibodies such as Tocilizumab have demonstrated effectiveness [12] leading to durable remission. Cytotoxic chemotherapies based on lymphoma protocols showed responses in TAFRO syndrome [13] or iMCD patients but is associated with chemotherapy-linked side effects and relapse is common. Rituximab, which is also used in iMCD, may be effective for disease control in TAFRO syndrome [14].

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] B. Castleman and V. W. Towne, “Case records of the Massachusetts general hospital: weekly clinicopathological exercises; founded by Richard C. Cabot,” *The New England Journal of Medicine*, vol. 251, no. 10, pp. 396–400, 1954.

[2] J. D. Soumerai, A. R. Sohani, and J. S. Abramson, “Diagnosis and management of Castleman disease,” *Cancer Control*, vol. 21, no. 4, pp. 266–278, 2014.

[3] E. E. Mylona et al., “Multicentric Castleman’s disease in HIV infection: a systematic review of the literature;” *AIDS Reviews*, vol. 10, pp. 25–35, 2008.

[4] D. C. Fajgenbaum, F. van Rhee, and C. S. Nabel, “HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy,” *Blood*, vol. 123, no. 19, pp. 2924–2933, 2014.

[5] H. Kawabata, K. Takai, M. Kojima et al., “Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012),” *Journal of Clinical and Experimental Hematopathology*, vol. 53, no. 1, pp. 57–61, 2013.

[6] K. Takai, K. Nikkuni, H. Shibuya, and H. Hashidate, “Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly;” [Rinshō ketsueki] *The Japanese journal of clinical hematology*, vol. 51, no. 5, pp. 320–325, 2010.

[7] Y. Masaki, H. Kawabata, K. Takai et al., “Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version,” *International Journal of Hematology*, 2016.

[8] N. Iwaki, D. C. Fajgenbaum, C. S. Nabel et al., “Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease,” *American Journal of Hematology*, vol. 91, no. 2, pp. 220–226, 2016.

[9] L. Fardet, L. Galicier, O. Lambotte et al., “Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome,” *Arthritis and Rheumatology*, vol. 66, no. 9, pp. 2613–2620, 2014.

[10] M. Inoue, M. Ankou, J. Hua, Y. Iwaki, and M. Hagiwara, “Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report;” *Journal of Clinical and Experimental Hematopathology*, vol. 53, no. 1, pp. 95–99, 2013.

[11] Y. Konishi, S. Takahashi, K. Nishi et al., “Successful treatment of TAFRO syndrome, a variant of multicentric Castleman’s disease, with cyclosporine a: Possible pathogenetic contribution of interleukin-2,” *Tohoku Journal of Experimental Medicine*, vol. 236, no. 4, pp. 289–295, 2015.

[12] H. Kawabata, S.-I. Kotani, Y. Matsumura et al., “Successful treatment of a patient with multicentric castleman’s disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody;” *Internal Medicine*, vol. 52, no. 13, pp. 1503–1507, 2013.

[13] S. Tedesco, L. Postacchini, L. Manfredi et al., “Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report;” *Experimental Hematology and Oncology*, vol. 4, no. 1, article 3, 2015.

[14] S. Hiramatsu, K. Ohmura, H. Tsuji et al., “Successful treatment by rituximab in a patient with TAFRO syndrome with cardiomyopathy;” *Japanese Journal of Clinical Immunology*, vol. 39, no. 1, pp. 64–71, 2016.